learned that when the
problem lies in your
DNA, there’s no simple
way to overcome

let's recode the coverage

news

7 DECEMBER 2020

Treatment with Investigational LentiGlobin™ Gene Therapy for Sickle Cell Disease (bb1111) Results in Complete Elimination of SCD-Related Severe Vaso-Occlusive Events in Phase 1/2 HGB-206 Clinical Study Presented at 62nd ASH Annual Meeting and Exposition

5 DECEMBER 2020

Long-Term Data for bluebird bio’s Gene Therapy for β-thalassaemia Show Patients Across Ages and Genotypes Achieve Transfusion Independence and Remain Free from Transfusions Up to Six Years

1 OCTOBER 2020

bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application (MAA) for elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD)

23 SEPTEMBER 2020

bluebird bio’s LentiGlobin™ for Sickle Cell Disease Gene Therapy (bb1111) Granted Priority Medicines (PRIME) Designation by European Medicines Agency

29 AUGUST 2020

bluebird bio Presents New Results from Clinical Development Programme of elivaldogeneautotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD),Including Updated Long-Term Data

12 JUNE 2020

New Data Show Near Elimination of Sickle Cell Disease-Related Vaso-Occlusive Crises and Acute Chest Syndrome with bluebird bio’s LentiGlobin™ Gene Therapy for Sickle Cell Disease at 25th EHA Congress

12 JUNE 2020

New Data from Phase 3 Studies Support Maintained Transfusion Independence* for Patients Across Genotypes Treated with betibeglogene autotemcel (LentiGlobin for β-thalassaemia) Gene Therapy

13 JANUARY 2020

bluebird bio Announces Launch in Germany of Zynteglo™

09 DECEMBER 2019

bluebird bio Presents New Data Demonstrating Long-Term Transfusion Independence* and Safety for LentiGlobin™ Gene Therapy for β-thalassaemia across genotypes at ASH Annual Meeting

07 DECEMBER 2019

bluebird bio Presents Data from Phase 1/2 HGB-206 Group C Study Demonstrating LentiGlobin™ Gene Therapy for Sickle Cell Disease (SCD) Produces Anti-sickling Haemoglobin Contributing 40% or More to Total Haemoglobin Following Six Months of Treatment

18 SEPTEMBER 2019

bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13^th European Pediatric Neurology Society (EPNS) Congress

14 JUNE 2019

bluebird bio Presents Long-Term Efficacy and Safety Data from Clinical Studies of LentiGlobin® Gene Therapy for Transfusion-Dependent β-Thalassaemia (TDT) at 24^th European Haematology Association (EHA) Congress

bluebird bio Presents New Data for LentiGlobin® Gene Therapy for Sickle Cell Disease (SCD) at 24^th European Haematology Association (EHA) Congress

03 JUNE 2019

bluebird bio Announces European Conditional Marketing Authorisation

29 MARCH 2019

bluebird bio Receives Positive Opinion from CHMP for Zynteglo™ (autologous CD34+ cells encoding β^A‑T87Qglobin gene) Gene Therapy for Patients 12 Years and Older with Transfusion Dependent β‑Thalassaemia (TDT) and Who Do Not Have a β⁰/β⁰ Genotype